Leber A W, Eichinger W, Rieber J, Lieber M, Schleger S, Ebersberger U, Deichstetter M, Vogel J, Helmberger T, Antoni D, Riess G, Hoffmann E, Kasel A M
Schulich Heart Center at Sunnybrook Health Science Center Toronto, Univ. of Toronto, Canada; Heart Center Munich Bogenhausen at Klinikum München Bogenhausen, Dept. of Cardiology, Munich, Germany.
Int J Cardiol. 2013 Oct 3;168(3):2658-64. doi: 10.1016/j.ijcard.2013.03.030. Epub 2013 Apr 12.
Prospective data on the usage of 3-dimensional imaging based annulus sizing on the outcome of TAVI is not available yet and there is general uncertainty about the optimal degree of oversizing. In the current study we therefore assessed a 3-D MSCT guided over-sizing approach and evaluated the clinical outcome of different degrees of oversizing.
TAVI-size-selection was done using systolic MSCT-annulus cross-sectional-area (CSA) measurements in 107 patients with severe aortic stenosis with the goal to oversize the 3rd generation balloon expandable Edwards Sapien XT (ESTV) device in relation to the native aortic annulus CSA.
Among different degrees of oversizing there were no differences in the occurrence of stroke, myocardial infarction and death. No aortic injuries were observed. The overall rate of >mild postprocedural aortic regurgitation (PAR) was 7.6%. Increasing oversizing ratios are associated with lower rates of >mild PAR (r = -0.236, p<0.02) with the lowest rate of >mild PAR in patients with area based oversizing ratios >25% and the highest rate in patients with oversizing ratios <15% (0% vs. 15.8%, p<0.02). The rate of postprocedural permanent pacemakers tended to be lower in patients with <15% oversizing compared to those with >25% oversizing (5.3 vs. 16.7%, p<0.23).
MSCT guided ESTV-device sizing is safe and is associated with significantly lower than previously reported rates for PAR. A device/annulus oversizing ratio of 15-25% based on area and 7-12% based on mean diameter appears to provide the best risk-benefit ratio in terms of PAR reduction and conduction disorders.
关于基于三维成像的瓣环尺寸测量在经导管主动脉瓣置入术(TAVI)结局方面的前瞻性数据尚未可得,并且对于最佳的尺寸过大程度普遍存在不确定性。因此,在本研究中我们评估了一种三维多层螺旋计算机断层扫描(MSCT)引导的尺寸过大方法,并评估了不同尺寸过大程度的临床结局。
在107例严重主动脉瓣狭窄患者中,使用收缩期MSCT瓣环横截面积(CSA)测量来进行TAVI尺寸选择,目标是相对于天然主动脉瓣环CSA使第三代球囊扩张式爱德华兹Sapien XT(ESTV)装置尺寸过大。
在不同的尺寸过大程度中,中风、心肌梗死和死亡的发生率没有差异。未观察到主动脉损伤。术后>轻度主动脉瓣反流(PAR)的总体发生率为7.6%。尺寸过大比例增加与>轻度PAR的发生率降低相关(r = -0.236,p<0.02),基于面积的尺寸过大比例>25%的患者中>轻度PAR的发生率最低,尺寸过大比例<15%的患者中发生率最高(0%对15.8%,p<0.02)。与尺寸过大比例>25%的患者相比,尺寸过大比例<15%的患者术后永久性起搏器的发生率倾向于更低(5.3%对16.7%,p<0.23)。
MSCT引导的ESTV装置尺寸选择是安全的,并且与显著低于先前报道的PAR发生率相关。基于面积的装置/瓣环尺寸过大比例为15 - 25%以及基于平均直径的为7 - 12%,在降低PAR和传导障碍方面似乎提供了最佳的风险效益比。